Sign In
Buy AMRN
$14.53
+0.0600 (+0.415%)
At Close: Jun 03, 2026
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG)
LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok
07:16pm, Friday, 07'th Jun 2024
LA BOUTIQUE, the leading Thai fashion designer brand celebrated for its neo-romantic and new vintage aesthetic, is thrilled to announce the grand opening of its latest flagship store at Gaysorn Amarin
Amarin Board of Directors Announces CEO Transition
07:30am, Tuesday, 04'th Jun 2024
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities --
-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [�
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
08:00am, Monday, 06'th May 2024
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is sche
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
10:46am, Friday, 03'rd May 2024
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
01:36pm, Wednesday, 01'st May 2024
Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.
Amarin Reports First Quarter 2024 Business Update and Financial Results
07:00am, Wednesday, 01'st May 2024
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients Citizen Petition Spotlig
Amarin Announces Results of Annual General Meeting of Shareholders
08:00am, Monday, 22'nd Apr 2024
- Shareholders Approve Share Repurchase Program of up to $50 Million - - Shareholders Approve Share Repurchase Program of up to $50 Million -
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
08:00am, Monday, 15'th Apr 2024
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, a
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
08:00am, Monday, 08'th Apr 2024
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
03:30pm, Saturday, 06'th Apr 2024
-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American Col
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
02:21pm, Thursday, 04'th Apr 2024
Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
Why Amarin Stock Was Rocketing Higher on Wednesday
04:13pm, Wednesday, 03'rd Apr 2024
Amarin's Vazkepa notched a crucial win with a European regulator. The medication earned an extension to its patent exclusivity on that market.
